---
annotation-target: bloodadvances.2022007508.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-16T14:12:26.728Z","updated":"2022-09-16T14:12:26.728Z","document":{"title":"bloodadvances.2022007508.pdf","link":[{"href":"urn:x-pdf:4aae2de9203198d3d6738d52cf7aafaa"},{"href":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022007508.pdf"}],"documentFingerprint":"4aae2de9203198d3d6738d52cf7aafaa"},"uri":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022007508.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/bloodadvances.2022007508.pdf","selector":[{"type":"TextPositionSelector","start":9033,"end":9725},{"type":"TextQuoteSelector","exact":"t is well accepted that patients with chronic lymphocytic leukemia (CLL) that are 83 asymptomatic and in early clinical phase do not require therapy.(1) Nevertheless, 84 cumulative data on the risk of clonal evolution (2-4) renewed the interest about an early 85 therapeutic intervention on patients at diagnosis who are likely to progress rapidly.(5) 86 Therefore, the identification at diagnosis of these patients has been an intense focus of 87 clinical research in the field of CLL. Prognostication in this setting has classically relied 88 upon a myriad of laboratory values, cytogenetic abnormalities, gene mutations or the 89 mutational  status  of  the  immunoglobulin  genes  ( IGHV)","prefix":"ust 2022  4 81 Introduction 82 I","suffix":".(6-10)  More  recently,  the 90"}]}]}
>```
>%%
>*%%PREFIX%%ust 2022  4 81 Introduction 82 I%%HIGHLIGHT%% ==t is well accepted that patients with chronic lymphocytic leukemia (CLL) that are 83 asymptomatic and in early clinical phase do not require therapy.(1) Nevertheless, 84 cumulative data on the risk of clonal evolution (2-4) renewed the interest about an early 85 therapeutic intervention on patients at diagnosis who are likely to progress rapidly.(5) 86 Therefore, the identification at diagnosis of these patients has been an intense focus of 87 clinical research in the field of CLL. Prognostication in this setting has classically relied 88 upon a myriad of laboratory values, cytogenetic abnormalities, gene mutations or the 89 mutational  status  of  the  immunoglobulin  genes  ( IGHV)== %%POSTFIX%%.(6-10)  More  recently,  the 90*
>%%LINK%%[[#^kqwj7jp8zp|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^kqwj7jp8zp
